trophic
Posted by trophic
April 25, 2025
April 25, 2025

CatalYm to Present New Data Demonstrating GDF-15 Blockade Enhances Efficacy of Antibody-Drug Conjugates at AACR 2025

CatalYm to Present New Data Demonstrating GDF-15 Blockade Enhances Efficacy of Antibody-Drug...

Read More
trophic
Posted by trophic
April 1, 2025
April 1, 2025

GDF-15 blockade: A multi-directional approach to potentiate cancer immunotherapy and alleviate cancer cachexia

Ignacio Melero, Kathrin Klar, Eugen Leo / Clin Transl Med. 2025; 15:e70280.

Read More
trophic
Posted by trophic
April 1, 2025
April 1, 2025

Neutralizing GDF-15 can overcome anti-PD-1 and anti-PD-L1 resistance in solid tumours

Ignacio Melero, Maria de Miguel Luken, Guillermo de Velasco, Elena Garralda, Juan...

Read More
trophic
Posted by trophic
January 9, 2025
January 9, 2025

CatalYm Appoints Scott Clarke CEO as Company Initiates Global Phase 2b Clinical Development Program for Visugromab

CatalYm Appoints Scott Clarke CEO as Company Initiates Global Phase 2b Clinical...

Read More
trophic
Posted by trophic
January 9, 2025
January 9, 2025

J.P. Morgan Healthcare Conference 2025

Jan 13 - Jan 16, 2025

Read More
trophic
Posted by trophic
December 11, 2024
trophic
Posted by trophic
October 11, 2024
October 11, 2024

CatalYm Announces Leadership Change

CatalYm Announces Leadership Change   Munich, Germany, October 11, 2024 – CatalYm...

Read More
trophic
Posted by trophic
November 8, 2023
November 8, 2023

GDF-15 neutralizing antibody visugromab increases intratumoral immune cell infiltration to support bispecific T-cell engagers

Sabrina Genssler, Daniel Schaetzlein, Eugen Leo, Markus Haake and Christine Schuberth-Wagner /...

Read More
trophic
Posted by trophic
November 8, 2023
November 8, 2023

SHP-1 is a central mediator of GDF-15 mediated adhesion inhibition in T-cells

Markus Haake, Neha Vashist, Beatrice Haack, Birgitt Fischer, Kristin Eichler, Matthias Kist,...

Read More
trophic
Posted by trophic
October 31, 2023
WordPress Cookie Notice by Real Cookie Banner